Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 54.6B 8.12B 6.96B 6.51B 5.95B 11.23B 778B 11.35B 77.05B 29.96B 391B 30.49B 29.83B 1,292B P/E 2026 *
40.6x
P/E 2027 * 31.9x
Enterprise Value 50.32B 7.49B 6.41B 6B 5.49B 10.35B 717B 10.46B 71.01B 27.61B 360B 28.11B 27.5B 1,191B EV / Sales 2026 *
6.2x
EV / Sales 2027 * 5.18x
Free-Float
61.13%
Yield 2026 *
0.73%
Yield 2027 * 1.14%
12:57am CIG Shanghai Declares Interim Dividend MT
08:50pm CIG Shanghai's H1 Profit More Than Doubles MT
08:31pm Asymchem Laboratories' H1 Profit Declines 16% MT
Aug. 24 Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Jul. 31 Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6% MT
Jul. 29 Shanghai Asymchem Biotechnology Development Co., Ltd. announced that it expects to receive CNY 1.239699995 billion in funding from Asymchem Laboratories Co., Ltd., Suzhou Gao Ling Qirui Healthcare Investment, L.P. and another investor CI
Jul. 27 AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building CI
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 175.98 Yuan From 132.37 Yuan, Keeps at Buy MT
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$131.48 From HK$115.43, Keeps at Buy MT
Jun. 11 Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026 CI
May. 27 Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates CI
May. 20 Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says RE
May. 15 Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026 CI
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 8.12B
-0.67%+5.39%+75.21%+127.54% 1,111B
+1.04%+4.07%+52.29%+65.39% 658B
-0.17%+5.67%+25.60%+80.40% 467B
-1.38%+4.02%+41.64%+42.38% 369B
-0.52%+2.72%+24.32%+41.06% 301B
-1.06%+4.76%+1.19%+12.65% 256B
+1.03%+5.83%+51.11%+72.96% 240B
-0.53%+2.34%-17.77%-53.66% 207B
+0.42%+5.63%+27.86%+92.24% 182B
Average -0.18%+4.49%+31.27%+53.44% 421.22B
Weighted average by Cap. -0.23%+4.68%+43.95%+73.01%

Financials

2026 *2027 *
Net sales 8.12B 1.21B 1.03B 968M 885M 1.67B 116B 1.69B 11.46B 4.45B 58.06B 4.53B 4.44B 192B 9.72B 1.45B 1.24B 1.16B 1.06B 2B 138B 2.02B 13.71B 5.33B 69.49B 5.43B 5.31B 230B
Net income 1.42B 211M 181M 169M 155M 292M 20.19B 295M 2B 778M 10.14B 792M 775M 33.55B 1.77B 263M 225M 211M 193M 364M 25.17B 367M 2.49B 970M 12.64B 987M 966M 41.82B
Net Debt -4.28B -636M -545M -510M -466M -880M -60.93B -889M -6.04B -2.35B -30.59B -2.39B -2.34B -101B -4.28B -637M -546M -511M -467M -881M -60.98B -890M -6.04B -2.35B -30.62B -2.39B -2.34B -101B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-